Physician profile
Pascale Vixama
NPI 1295176774
$1,762.87
in general payments reported to CMS, 2019-2025
14 companies · $56.83 in 2025
The $56.83 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $609 · 2023: $364 · 2024: $536 · 2025: $56.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.42 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $460.36 | 2021-2024 | Relistor, Xifaxan |
| Scilex Pharmaceuticals INC. | $163.14 | 2024 | |
| Glaxosmithkline, LLC. | $98.70 | 2022-2023 | Trelegy Ellipta |
| Amgen INC. | $50.14 | 2023-2024 | Otezla, Repatha, Prolia |
| Janssen Biotech, INC. | $46.60 | 2022-2023 | Symtuza |
| Lilly USA, LLC | $45.96 | 2022 | |
| Shield Therapeutics INC | $45.91 | 2023 | Accrufer |
| Horizon Therapeutics Plc | $44.45 | 2022 | |
| Exact Sciences Corporation | $34.23 | 2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $34.17 | 2021 | |
| Pfizer INC. | $25.00 | 2023 | |
| Forte Bio-Pharma LLC | $22.60 | 2025 | Prolate, Nalocet, Tanlor |
| Orexo US, INC. | $16.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascale Vixama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.